Search research articles
Contact Us
Filters
Showing results (41-50 of 127) with videos related to
Page
of 13
Sort By:
Anti-Cancer Drugs
|
February 9, 2018
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience
Claudio Cerchione, Davide Nappi, Anna E Pareto, et al.
Insights Into Imaging
|
December 3, 2020
Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic
Alice Rossi, Andrea Prochowski Iamurri, Claudio Cerchione, et al.
Expert Opinion on Drug Safety
|
April 15, 2021
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
Giovanni Marconi, Maria Benedetta Giannini, Gianmarco Bagnato, et al.
The Oncologist
|
January 11, 2018
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, et al.
Minerva Medica
|
September 21, 2020
Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia
Raffaele Palmieri, Francesco Buccisano, Luca Maurillo, et al.
Minerva Medica
|
September 21, 2020
New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia
Francesco Lanza, Enrico Maffini, Francesco Saraceni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 26, 2018
Safety and comfort of domestic bortezomib injection in real-life experience
Claudio Cerchione, Davide Nappi, Anna Emanuele Pareto, et al.
Case Reports in Hematology
|
November 22, 2016
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
Claudio Cerchione, Davide Nappi, Maria Di Perna, et al.
Annals of Hematology
|
February 15, 2018
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy
Alessandra Romano, Nunziatina Laura Parrinello, Calogero Vetro, et al.
Hematology Reports
|
November 24, 2025
The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities
Mina Y George, Nada K Gamal, Daniel E Mansour, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 127) with videos related to
Sort By:
Page
of 13
Anti-Cancer Drugs
|
February 9, 2018
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience
Claudio Cerchione, Davide Nappi, Anna E Pareto, et al.
Insights Into Imaging
|
December 3, 2020
Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic
Alice Rossi, Andrea Prochowski Iamurri, Claudio Cerchione, et al.
Expert Opinion on Drug Safety
|
April 15, 2021
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
Giovanni Marconi, Maria Benedetta Giannini, Gianmarco Bagnato, et al.
The Oncologist
|
January 11, 2018
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, et al.
Minerva Medica
|
September 21, 2020
Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia
Raffaele Palmieri, Francesco Buccisano, Luca Maurillo, et al.
Minerva Medica
|
September 21, 2020
New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia
Francesco Lanza, Enrico Maffini, Francesco Saraceni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 26, 2018
Safety and comfort of domestic bortezomib injection in real-life experience
Claudio Cerchione, Davide Nappi, Anna Emanuele Pareto, et al.
Case Reports in Hematology
|
November 22, 2016
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
Claudio Cerchione, Davide Nappi, Maria Di Perna, et al.
Annals of Hematology
|
February 15, 2018
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy
Alessandra Romano, Nunziatina Laura Parrinello, Calogero Vetro, et al.
Hematology Reports
|
November 24, 2025
The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities
Mina Y George, Nada K Gamal, Daniel E Mansour, et al.
Page
of 13